Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-06-24
1998-02-03
Spivack, Phyllis G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3144
Patent
active
057145059
DESCRIPTION:
BRIEF SUMMARY
FIELD OF INVENTION
The present invention relates to a novel method of treating psoriasis.
BACKGROUND OF THE INVENTION
Psoriasis is a primary disease of the skin characterized by well-demarcated, inflammatory papules and plaques, which are typically covered by thickened scales. It is a disease of increased proliferation of epidermal cells, the precise cause of which is unknown.
The incidence of psoriasis in e.g. the U.S. is about 2%. About 3% of whites and 1% of blacks are affected.
Therapeutic efforts in psoriasis are aimed at decreasing the proliferative rate of the epidermis either by direct action on cell division, or through agents that reduce the inflammatory response or vascular permeability. For patients with localised, limited psoriasis, topical administration of calcipotriol (D-vitamin derivative), dithranol or corticosteroids are the most convenient outpatient therapy. For patients with more extensive disease topical treatment followed by eradication with UV light may be necessary.
For patients with extensive disease a systemic antimitotic agent, such as methotrexate, can be used.
Extensive psoriasis can also be treated with photochemotherapy. In this regimen, orally administered, 8-methoxypsoralen produces photosensitization, which is followed by exposure to ultraviolet A (PUVA, 320 nm).
The retinoids, particularly eretrinate, either alone or in combination with PUVA, are also effective treatment for psoriasis. Furthermore, during acute attacks of pustular psoriasis, systemic steroids have been the therapy of choice.
In view of postulated immunologic mechanisms it is interesting that cyclosporin A has been shown to be an effective treatment. Considering the risk for complications, such treatment should, however, be reserved for patients with recalcitrant, debilitating psoriasis when the benefit outweighs the potential risk of complications.
As will be clear from the above, there is a need for new, alternative and improved methods for treating psoriasis. The present invention provides a novel method for the treatment of psoriasis.
DETAILED DESCRIPTION OF THE INVENTION
It has been found according to the invention that administration of omeprazole to patients affected by psoriasis results in disappearance of or great improvement of the symptoms of psoriasis. This applies to all manifestations of psoriasis.
Omeprazole is a pharmaceutical agent having the formula ##STR1## and is used in therapy for treatment of gastric acid related diseases, such as gastric ulcer.
Omeprazole can be administered orally, rectally or parenterally in neutral form or in the form of a basic salt, such as the Mg.sup.2+, Ca.sup.2+, Na.sup.+, or K.sup.+ salts, preferably the Mg.sup.2+ or Na.sup.+ salts. While the effect on the symptoms of psoriasis have been established in patients who have taken omeprazole by the oral route, it is believed that the effect of omeprazole on psoriasis is a systemic effect which is not dependent on what mode of administration that is used, and that accordingly the healing effect on psoriasis will be seen also with other routes of administration such as rectal or parenteral administration.
Omeprazole can also be used in the form of a substantially pure enantiomer, or a salt thereof such as the salts mentioned above.
The commercially available pharmaceutical formulations of omeprazole will normally be used also for the use of omeprazole for treating psoriasis. Examples of such commercially available formulations are: omeprazole as active ingredient.
Being a labile compound with poor storage stability at neutral or acid pH, omeprazole formulations must be produced with great care. Examples of ways of producing stable formulations are given in e.g. EP-A-247,983.
The dose of omeprazole to be administered at treatment of psoriasis will vary depending on factors such as the severity of the disease and the status of the patient. The dosage range at oral, rectal as well as i.v. administration may be in the interval from 1 to 100 mg per day. Normally, an amount of from 10 to 40 mg of omeprazole a d
REFERENCES:
Hasselkus, W. "Afheilung einer chronischen Psoriasis vulgaris unter Omeprazol", Deutsche Med. Wochenschr (Germany) 118 (1-2): 46, 1993.
Astra Aktiebolag
Spivack Phyllis G.
LandOfFree
Method for treatment of psoriasis, by omeprazole or related comp does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treatment of psoriasis, by omeprazole or related comp, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treatment of psoriasis, by omeprazole or related comp will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-662675